Obesity, 32(8), 1469-1480
Conflict of interest DK has received research support from Sanofi, Tanabe Pharma, Terumo, Behringer Ingelheim, Kyowa Kirin, Sumitomo Dainippon Pharma, Ono Pharmaceutical and Takeda Pharmaceutical as well as speaker honoraria from Novo Nordisk Pharma, Sanofi, and Takeda Pharmaceutical
FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
Eli Lilly: Tirzepatide/Mounjaro Lily initially developed Tirzepatide as a dual agonist, with a half-life of around 5 days, for the treatment of T2DM
This way, you can be confident youre receiving a product thats been fully vetted for safety, strength, and quality
Pfizer.Inc Amgen, Inc